CNN - The US Food and Drug Administration has approved a second gene therapy for cancer, the first to target non-Hodgkin lymphomas.
The therapy, Yescarta (axicabtagene ciloleucel), is intended for adult patients with certain types of large B-cell lymphoma after other treatments fail.
Non-Hodgkin lymphomas, which account for about 4% of all cancers in the United States, are malignancies that begin in certain cells of the immune system. An estimated 72,000 new cases are diagnosed each year in the US.
Diffuse large B-cell lymphoma, which is the most common form of non-Hodgkin lymphoma, represents about one in three newly diagnosed cases...>>>
Posta un commento